Adoptive cell-transfer (ACT) therapy, which involves the ex vivo expansion and reinfusion of tumor-reactive T cells such as tumor-infiltrating lymphocytes (TILs) and, genetically-retargeted T cells with conventional T-cell receptors (TCRs) or chimeric antigen receptors (CARs), is emerging as a potential curative treatment for patients with advanced-stage cancer. Here, CARS1 is linked to neoplasm.